65646-68-6
基本信息
芬维A胺
4-HYDROXYPHENYLRETINAMIDE
FENRETINIDE
N-(4-HYDROXYPHENYL)-ALL-TRANS RETINAMIDE
N-(4-HYDROXYPHENYL)RETINAMIDE
RETINAMIDE
RETINOIC ACID P-HYDROXYANILIDE
hpr
n-(4-hydroxyphenyl)-retinamid
p-Hydroxyphenylretinamide
4-HPR, Fenretinide, N-(4-Hydroxyphenyl)retinamide
(2E,4E,6E,8E)-N-(4-Hydroxyphenyl)-3,7-dimethyl-9-(2,6,6-trimethyl-1-cyclohexen-1-yl)-2,4,6,8-nonatetraenamide
Fenretinimide
物理化学性质
| 熔点 | 162-163°C |
| 沸点 | 597.6±42.0 °C(Predicted) |
| 密度 | 1.081±0.06 g/cm3(Predicted) |
| 储存条件 | −20°C |
| 储存条件 | -20°C |
| 溶解度 | 可溶于氯仿（少许）、甲醇（少许） |
| 酸度系数(pKa) | 9.98±0.26(Predicted) |
| 形态 | 橙色固体 |
| 颜色 | 黄色 |
| 生物来源 | synthetic (organic) |
| 最大波长(λmax) | 362nm(MeOH)(lit.) |
| Merck | 14,3998 |
| 稳定性 | 对光敏感，应避光保存 |
| InChIKey | AKJHMTWEGVYYSE-FXILSDISSA-N |
| SMILES | C(NC1=CC=C(O)C=C1)(=O)/C=C(/C=C/C=C(/C=C/C1C(C)(C)CCCC=1C)\C)\C |
| CAS 数据库 | 65646-68-6(CAS DataBase Reference) |
安全数据
| 危险性符号(GHS) |   GHS07,GHS08 |
| 警示词 | 危险 |
| 危险性描述 | H302+H312+H332-H315-H319-H335-H360 |
| 防范说明 | P201-P280-P301+P312+P330-P302+P352+P312-P304+P340+P312-P308+P313 |
| 危险品标志 | T |
| 危险类别码 | 60-61-20/21/22-36/37/38 |
| 危险类别码 | R60-R61-R20/21/22-R36/37/38 |
| 安全说明 | 53-26-36/37/39-45-52 |
| 安全说明 | S53-S26-S36/37/39-S45 |
| WGK Germany | 3 |
| WGK Germany | 3 |
| RTECS号 | VH6420000 |
| 海关编码 | 2924297099 |
| 存储类别 | 6.1C - Combustible acute toxic Cat.3 toxic compounds or compounds which causing chronic effects |
| 危险性类别 | Acute Tox. 4 Dermal Acute Tox. 4 Inhalation Acute Tox. 4 Oral Eye Irrit. 2 Repr. 1B Skin Irrit. 2 STOT SE 3 |
知名试剂公司产品信息
维甲酰酚胺价格(试剂级)
| 报价日期 | 产品编号 | 产品名称 | CAS号 | 包装 | 价格 |
| 2026/09/15 | HY-15373R | 维甲酰酚胺 Fenretinide (Standard) | 65646-68-6 | 5 mg | 704元 |
| 2026/09/15 | HY-15373R | 维甲酰酚胺 Fenretinide (Standard) | 65646-68-6 | 10 mg | 1056元 |
| 2026/09/15 | HY-15373R | 维甲酰酚胺 Fenretinide (Standard) | 65646-68-6 | 25 mg | 1800元 |
常见问题列表
Fenretinide (4-HPR) exerts not just acute but also long term antitumor activity in selected T-ALL cell lines. Fenretinide inhibits DES activity in CCRF-CEM leukemia cells in a dose and time dependent manner, leading to a concomitant increase of the endogenous cellular dhCer content. Fenretinide (3 μM)-induced dhCer accumulation in both CCRF-CEM and Jurkat cells. Ceramide inhibition with fenretinide protects insulin signaling. Fenretinide prevents lipid-induced reductions in insulin-stimulated glucose uptake. Fenretinide inhibits OVCAR-5 cell proliferation and viability at concentrations higher than 1 microM, with 70-90% growth inhibition at 10 microM. Fenretinide (1 microM) significantly inhibits OVCAR-5 invasion after 3 days preincubation. Endothelial cells treated with 1 microM 4-HPR fails to form tubes, but forms small cellular aggregates.
Fenretinide (4-HPR) (10 mg/kg, i.p.) selectively inhibits ceramide accumulation HFD-fed male C57Bl/6 mice. Fenretinide treatment improves glucose tolerance and insulin sensitivity as determined by both glucose and insulin tolerance tests. Addition of 25 mg/kg ketoconazole to Fenretinide in NOD/SCID mice increased 4-HPR plasma levels.